Transparency in RWE: an update – Richard White

Return to the Spotlight: rare diseases and innovative therapies programme Learning objectives  Why does transparency in real-world evidence (RWE) matter? Why is transparency important for trust in RWE? What lessons we can learn from randomized controlled trials? What are the key issues and what are we doing about them? How should we best plan, design, execute and communicate RWE? What major initiatives are helping to increase transparency in RWE? Speaker biography Richard White is Chief Operating Officer at Oxford PharmaGenesis (UK), a global, independent HealthScience communications consultancy. In his 20 years in the industry, Richard founded Oxford PharmaGenesis Value Demonstration...